Tumor-derived soluble MICs impair CD3+CD56+ NKT-like cell cytotoxicity in cancer patients

Immunology Letters

Volumn 120, Issue 1-2, 2008, Pages 65-71

  Wang, Huiming ^a   Yang, Di ^a   Xu, Wenyue ^a   Wang, Yiqin ^a   Ruan, Zhihua ^a   Zhao, Tingting ^a   Han, Junfeng ^a   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD3+CD56+ NKT like cells; MHC class I chain related molecules (MICs); NKG2D; Tumor

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; NEUTRALIZING ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER IMMUNOLOGY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNE RESPONSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR REJECTION;

ANTIGENS, CD3; ANTIGENS, CD56; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NATURAL KILLER T-CELLS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 50449096575     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.07.001     Document Type: Article

References (42)

1. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 5 (2002) 625-636
2. + T cells. Blood 103 (2004) 3065-3072
3. Groh V., Bruhl A., El-Gabalawy H., Nelson J.L., and Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 100 16 (2003) 9452-9457
4. Cerwenka A., Bakker A.B., McClanahan T., Wagner J., Wu J., Phillips J.H., et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12 (2000) 721-727
5. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., and Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1 (2000) 119-126
6. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285 (1999) 727-729
7. Jamieson A.M., et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17 (2002) 19-29
8. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3 (2003) 781-790
9. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 5428 (1999) 730-732
10. Diefenbach A., and Raulet D.H. Innate immune recognition by stimulatory immunoreceptors. Curr Opin Immunol 15 (2003) 37-44
11. Ravetch J.V., and Lanier L.L. Immune inhibitory receptors. Science 290 5489 (2000) 84-89
12. Groh V., et al. Co-stimulation of CD8 + αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2 (2001) 255-260
13. Maasho K., Opoku-Anane J., Marusina A.I., Coligan J.E., and Borrego F. NKG2D is a costimulatory receptor for human naive CD8+T cells. J Immunol 174 8 (2005) 4480-4484
14. Markiewicz M.A., Carayannopoulos L.N., Naidenko O.V., Matsui K., Burack W.R., Wise E.L., et al. Costimulation through NKG2D enhances murine CD8+CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 175 (2005) 2825-2833
15. Vivier E., Tomasello E., and Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?. Curr Opin Immunol 14 (2002) 306-311
16. Cerwenka A., and Lanier L.L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61 (2003) 335-343
17. Osaki T., Saito H., Yoshikawa T., Matsumoto S., Tatebe S., Tsujitani S., et al. Decreased NKG2D expression on CD8+T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 13 2 Pt 1 (2007) 382-387
18. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
19. Salih H.R., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102 (2003) 1389-1396
20. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B., et al. Evasion from NK cell immunity by MHC class I chainrelated molecules expressing colon adenocarcinoma. J Immunol 171 (2003) 6891-6899
21. Oppenheim D.E., Roberts S.J., Clarke S.L., Filler R., Lewis J.M., Tigelaar R.E., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6 9 (2005) 928-937
22. Coudert J.D., Zimmer J., Tomasello E., Cebecauer M., Colonna M., Vivier E., et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106 5 (2005) 1711-1717
23. Kriegeskorte A.K., Gebhardt F.E., Porcellini S., Schiemann M., Stemberger C., Franz T.J., et al. NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc Natl Acad Sci USA 102 33 (2005) 11805-11810
24. Satoh M., Seki S., Hashimoto W., Ogasawara K., Kobayashi T., Kumagai K., et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 157 9 (1996) 3886-3892
25. Giroux M., and Denis F. CD1d-unrestricted human NKT-like cells release chemokines upon Fas engagement. Blood 105 2 (2005) 703-710
26. Ortaldo J.R., Winkler-Pickett R.T., Yagita H., and Young H.A. Comparative studies of CD3- and CD3+CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 136 2 (1991) 486-495
27. Lu P.-H., and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo anti-tumor activity in mice with severe combined immunodeficiency. J Immunol 153 (1994) 1687-1696
28. Baxevanis C.N., Gritzapis A.D., and Papamichail M. In vivo antitumor activity of NKT-like cells activated by the combination of IL-12 and IL-18. J Immunol 171 6 (2003) 2953-2959
29. Saeterdal I., thor Straten P., Myklebust J.H., Kirkin A.F., Gjertsen M.K., and Gaudernack G. Generation and characterization of gp100 peptide-specific NK-T cell clones. Int J Cancer 75 5 (1998) 794-803
30. Baxevanis C.N., Gritzapis A.D., Tsitsilonis O.E., Katsoulas H., and Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3+CD56+ (natural killer T) lymphocytes. Int J Cancer 98 (2002) 864-872
31. Wajchman H.J., Pierce C.W., Varma V.A., Issa M.M., Petros J., and Dombrowski K.E. Ex vivo expansion of CD8 + CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. Cancer Res 64 3 (2004) 1171-1180
32. Sconocchia G., Lau M., Provenzano M., Rezvani K., Wongsena W., Fujiwara H., et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106 10 (2005) 3666-3672
33. Chan J.K., Hamilton C.A., Cheung M.K., Karimi M., Baker J., Gall J.M., et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12 6 (2006) 1859-1867
34. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., and Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114 4 (2004) 560-568
35. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 1 (2007) 1-14
36. Rivoltini L., Canese P., Huber V., Iero M., Pilla L., Valenti R., et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. Expert Opin Biol Ther 5 4 (2005) 463-476
37. González S., Groh V., and Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298 (2006) 121-138
38. Lanier L.L. NKG2D in innate and adaptive immunity. Adv Exp Med Biol 560 (2005) 51-56
39. + killer cells. Ann Hematol 74 (1997) 51-56
40. Cohavy O., and Targan S.R. CD56 marks an effector T cell subset in the human intestine. J Immunol 178 9 (2007) 5524-5532
41. + NK T and γδ T cells from cord blood of human neonates. Clin Exp Immunol 113 (1998) 220-228
42. Dasgupta S., Bhattacharya-Chatterjee M., O'Malley Jr. B.W., and Chatterjee S.K. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 175 8 (2005) 5541-5550